Inverness gets new glucose technology with LXN
This article was originally published in Clinica
Executive Summary
Inverness Medical Technology is to acquire LXN, a privately owned US diabetes measurement company, which has the first and only US FDA approved glycated protein test, as well as offering a standard self-test blood glucose fingerstick test. The move has the potential to propel Inverness into direct competition with its exclusive distribution partner, Johnson & Johnson, with an enhanced glucose monitor. This technology is unavailable to J&J.